Premium
Medium‐chain triglycerides supplement therapy with a low‐carbohydrate formula can supply energy and enhance ammonia detoxification in the hepatocytes of patients with adult–onset type II citrullinemia
Author(s) -
Hayasaka Kiyoshi,
Numakura Chikahiko,
Yamakawa Mitsunori,
Mitsui Tetsuo,
Watanabe Hisayoshi,
Haga Hiroaki,
Yazaki Masahide,
Ohira Hiromasa,
Ochiai Yasuo,
Tahara Toshiyuki,
Nakahara Tamio,
Yamashiki Noriyo,
Nakayama Takahiro,
Kon Takashi,
Mitsubuchi Hiroshi,
Yoshida Hiroshi
Publication year - 2018
Publication title -
journal of inherited metabolic disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.462
H-Index - 102
eISSN - 1573-2665
pISSN - 0141-8955
DOI - 10.1007/s10545-018-0176-1
Subject(s) - citrullinemia , hyperammonemia , medicine , endocrinology , glutamine , argininosuccinate synthase , citrulline , biology , biochemistry , arginine , amino acid
Citrin, encoded by SLC25A13 , constitutes the malate‐aspartate shuttle, the main NADH‐shuttle in the liver. Citrin deficiency causes neonatal intrahepatic cholestasis (NICCD) and adult–onset type II citrullinemia (CTLN2). Citrin deficiency is predicted to impair hepatic glycolysis and de novo lipogenesis, resulting in hepatic energy deficit. Secondary decrease in hepatic argininosuccinate synthetase (ASS1) expression has been considered a cause of hyperammonemia in CTLN2. We previously reported that medium–chain triglyceride (MCT) supplement therapy with a low–carbohydrate formula was effective in CTLN2 to prevent a relapse of hyperammonemic encephalopathy. We present the therapy for six CTLN2 patients. All the patients’ general condition steadily improved and five patients with hyperammonemic encephalopathy recovered from unconsciousness in a few days. Before the treatment, plasma glutamine levels did not increase over the normal range and rather decreased to lower than the normal range in some patients. The treatment promptly decreased the blood ammonia level, which was accompanied by a decrease in plasma citrulline levels and an increase in plasma glutamine levels. These findings indicated that hyperammonemia was not only caused by the impairment of ureagenesis at ASS1 step, but was also associated with an impairment of glutamine synthetase (GS) ammonia‐detoxification system in the hepatocytes. There was no decrease in the GS expressing hepatocytes. MCT supplement with a low–carbohydrate formula can supply the energy and/or substrates for ASS1 and GS, and enhance ammonia detoxification in hepatocytes. Histological improvement in the hepatic steatosis and ASS1‐expression was also observed in a patient after long‐term treatment.